RxDoctor Payments Data

John Tsai, MD

Cardiovascular Disease · Canton, OHNPI 1003859091

Payments from drug & device makers

$7,537in general payments, 2019–2025

Across 497 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$992
  • Amgen$891
  • Boehringer Ingelheim$871
  • AstraZeneca$712
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$80%
  • Food & beverage$7,47199%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,537 in reported general payments places this provider in the 70th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$114,253
Medicare patients
1,005
Services billed
1,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan536$622,397
EliquisApixaban561$526,410
JardianceEmpagliflozin521$521,537
XareltoRivaroxaban415$440,023
FarxigaDapagliflozin Propanediol173$149,428
Repatha SureclickEvolocumab155$126,742
VascepaIcosapent Ethyl29$11,812
Praluent PenAlirocumab17$11,238
Metoprolol Succinate703$10,317
Bumetanide355$10,064
BrilintaTicagrelor13$9,726
Atorvastatin Calcium752$6,529
Carvedilol637$5,042
Ezetimibe234$4,583
Dofetilide38$3,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,394$622,397536 claims
PfizerEliquis$193$526,410561 claims
Boehringer IngelheimJardiance$871$521,537521 claims
Johnson & JohnsonXarelto$1,013$440,023415 claims
AstraZenecaFarxiga, Brilinta$712$159,154186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →